Vanda Pharmaceuticals 2017 Corporate Presentation

Vanda Pharmaceuticals' 2017 corporate strategy presentation outlining long-term growth plans, including commercialization of HETLIOZ® for Non-24 treatment and Fanapt® for schizophrenia. The company focuses on expanding geographies, lifecycle management, and developing innovative therapies in niche therapeutic markets.